What is HC Wainwright’s Forecast for ZVRA Q2 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Investment analysts at HC Wainwright issued their Q2 2025 earnings estimates for Zevra Therapeutics in a research note issued on Wednesday, July 2nd. HC Wainwright analyst B. Folkes anticipates that the company will post earnings per share of ($0.09) for the quarter. HC Wainwright has a “Buy” rating and a $26.00 price target on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Zevra Therapeutics’ Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.27) EPS, FY2026 earnings at $0.72 EPS, FY2027 earnings at $1.92 EPS, FY2028 earnings at $3.50 EPS and FY2029 earnings at $3.69 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.15. The business had revenue of $20.40 million for the quarter, compared to analyst estimates of $16.96 million. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. During the same quarter in the prior year, the company posted ($0.40) earnings per share.

A number of other equities analysts also recently weighed in on the stock. Guggenheim boosted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, March 13th. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. JMP Securities set a $18.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd. Finally, Canaccord Genuity Group lifted their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, March 13th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Zevra Therapeutics presently has an average rating of “Buy” and an average target price of $23.14.

Zevra Therapeutics Stock Up 4.0%

NASDAQ:ZVRA opened at $9.79 on Friday. The firm has a market capitalization of $535.04 million, a price-to-earnings ratio of -5.15 and a beta of 1.97. The company has a quick ratio of 2.93, a current ratio of 3.02 and a debt-to-equity ratio of 1.46. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $10.03. The stock’s 50 day moving average price is $8.63 and its two-hundred day moving average price is $8.09.

Institutional Trading of Zevra Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its holdings in Zevra Therapeutics by 51.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company’s stock valued at $172,000 after acquiring an additional 6,966 shares during the period. BNP Paribas Financial Markets bought a new position in shares of Zevra Therapeutics during the fourth quarter worth approximately $53,000. Millennium Management LLC lifted its holdings in Zevra Therapeutics by 138.2% during the 4th quarter. Millennium Management LLC now owns 233,132 shares of the company’s stock worth $1,944,000 after purchasing an additional 135,246 shares during the last quarter. Deutsche Bank AG lifted its holdings in Zevra Therapeutics by 25.4% during the 4th quarter. Deutsche Bank AG now owns 50,906 shares of the company’s stock worth $425,000 after purchasing an additional 10,306 shares during the last quarter. Finally, ProShare Advisors LLC bought a new stake in Zevra Therapeutics in the 4th quarter valued at $145,000. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.